Core Viewpoint - A class action lawsuit has been filed against Coupang, Inc. for allegedly making false statements regarding its cybersecurity and regulatory compliance during the specified Class Period from May 7, 2025, to December 16, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Coupang had inadequate cybersecurity measures, which increased the risk of a data breach and potential regulatory scrutiny [3]. - Investors became aware of the company's cybersecurity issues through revelations starting in November 2025, which indicated that a former employee had access to sensitive customer information for nearly six months without detection [4]. - Following these disclosures, the price of Coupang securities experienced significant declines [4]. Group 2: Investor Information - Investors who purchased Coupang securities during the Class Period have until February 17, 2026, to seek appointment as lead plaintiff representatives [2]. - The law firm Berger Montague PC is leading the class action and provides contact information for interested investors [5]. Group 3: Company Overview - Coupang is headquartered in Seattle, Washington, and operates a diverse platform that includes retail, restaurant delivery, video streaming, and fintech services primarily for users in South Korea [2].

Core Insights - Commvault Systems, Inc. is under investigation for potential violations of federal securities laws, as announced by Levi & Korsinsky [1] - The company reported a 40% growth in SaaS ARR, reaching $364 million for Q3 fiscal 2026, but this represents a deceleration from the 56% growth reported in Q2 fiscal 2026 [2] - Following the earnings report, Commvault's stock experienced a significant decline of over 31% on January 27, 2026 [3] Financial Performance - Commvault's SaaS ARR grew to $364 million, marking a 40% increase year-over-year [2] - The company noted that 60% of its deals closed in the last few weeks of the quarter, indicating a potential surge in sales activity towards the end of the reporting period [2] - The growth rate of 40% in SaaS ARR is a notable slowdown compared to the previous quarter's growth of 56% [2] Market Reaction - The stock price of Commvault fell by over 31% on the day the financial results were announced, reflecting investor concerns regarding the deceleration in growth [3]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Vistagen Therapeutics, Inc. on behalf of investors who purchased or acquired the company's common stock between April 1, 2024, and December 16, 2025, alleging misrepresentations related to the company's clinical trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made misrepresentations concerning the Company's Phase 3 PALISADE-3 trial study of fasedienol, which is an investigational pherine candidate for the acute treatment of social anxiety disorder [4]. - Investors who wish to serve as lead plaintiff must file papers by March 16, 2026, and participation as a lead plaintiff is not required to share in any recovery [3]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for its clients since 1993 and has a strong track record in class action litigation [5].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Richtech Robotics Inc. ("Richtech†or the "Company†) (NASDAQ: RR) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON RICHTECH ROBOTICS INC. (RR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened. ...

Core Viewpoint - The Ultragenyx class action lawsuit alleges that the company and its executives made misleading statements regarding the efficacy of setrusumab in treating Osteogenesis Imperfecta, leading to significant stock price declines when the truth was revealed [4][5][6]. Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects and downplayed the risks associated with the Phase III Orbit study, which ultimately failed to show statistically significant results [4]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance, resulting in a stock price drop of over 25% [5]. - On December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, causing a further stock price decline of more than 42% [6]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx stock during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities class action recoveries, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [8].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - Integer also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, a decline of over 32%, from $109.11 per share on October 22, 2025, to $73.89 per share on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of New York, titled Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. - Investors have until April 3, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Plug Power specializes in hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets, and develops infrastructure such as hydrogen production plants [4]. Group 3: Financial Events Leading to Stock Drops - On October 7, 2025, Plug Power announced the departure of CEO Andrew Marsh and President Sanjay Shrestha, resulting in a stock price drop of $0.26 per share, or 6.3%, from $4.13 to $3.87 [5]. - On November 10, 2025, the company suspended activities under the DOE loan program, causing a further drop of $0.09 per share, or 3.4%, from $2.65 to $2.56 [6]. - On November 13, 2025, it was reported that Plug Power confirmed the suspension of plans to construct six hydrogen production facilities, leading to a stock price decline of $0.48 per share, or 17.6%, from $2.49 to $2.25 [7]. Group 4: Allegations of Misrepresentation - The lawsuit alleges that Plug Power materially overstated the likelihood of receiving DOE loan funds and the construction of necessary hydrogen production facilities [4].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. and its senior executives for securities fraud following a significant drop in stock price attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Denha v. BellRing Brands, Inc., No. 1:26-cv-00575 [2]. - Investors have until March 23, 2026, to request to lead the case [2]. Group 2: Company Background - BellRing Brands develops, markets, and sells "convenient nutrition" products, primarily known for its Premier Protein ready-to-drink protein shakes [3]. - The company previously claimed that its sales growth was due to increased consumer demand and various positive factors, while downplaying competitive pressures [3]. Group 3: Stock Performance and Impact - On May 6, 2025, BellRing's CFO indicated that several key retailers had reduced their inventory levels, leading to a projected mid-single-digit headwind for Q3 growth, resulting in a stock price drop of $14.88 per share, or 19% [4]. - Following the Q3 2025 financial results reported on August 4, 2025, which included a narrowed fiscal year outlook, the stock dropped by $17.46 per share, nearly 33%, the next day [5][6].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Ardent Health operates acute care hospitals and healthcare facilities, with a focus on the collection of accounts receivable [4]. Allegations of Fraud - The lawsuit claims that Ardent Health misrepresented its process for determining the collectability of accounts receivable, stating it relied on "detailed reviews of historical collections," while in reality, it used a "180-day cliff" method that inflated reported accounts receivable and delayed loss recognition [4]. Stock Performance Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5]. Legal Proceedings - Investors have until March 9, 2026, to request to lead the case in the U.S. District Court for the Middle District of Tennessee, under the caption Postiwala v. Ardent Health, Inc., et al. [3].

Core Viewpoint - SLM Corporation, also known as Sallie Mae, is facing a securities fraud lawsuit due to alleged misleading statements regarding its financial stability and loan delinquency rates during the class period from July 25, 2025, to August 14, 2025 [1] Group 1: Lawsuit Details - The Rosen Law Firm is reminding investors who purchased SLM securities during the class period of the February 17, 2026, deadline to become a lead plaintiff in the class action lawsuit [1] - The lawsuit claims that SLM made false and misleading statements about its early-stage delinquencies and the effectiveness of its loss mitigation and loan modification programs [1] - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [1] Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [1] - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019, and has been recognized for its performance in securities class action settlements [1] - Investors have the option to remain absent class members and are not required to serve as lead plaintiffs to share in any potential recovery [1]